Finilac vet.

1 x 3 ml

Oral solution

Active substance

Cabergoline : 50 mikg/ml

ATC code

QG02CB03 Cabergoline

QG02CB Prolactine inhibitors

QG02C Other gynecologicals

QG02 Other gynecologicals

QG Genito urinary system and sex hormones

Species

Dogs and cats.

Indications

Treatment of false pregnancy in bitches.

Suppression of lactation in bitches and queens.

Dose to be administered and administration route

Oral use.

The veterinary medicinal product should be administered orally either directly into the mouth or by mixing with food.

The dosage is 0.1 ml/kg bodyweight (equivalent to 5 microgram/kg bodyweight of cabergoline) once daily for 4-6 consecutive days, depending on the severity of the clinical condition.

If the signs fail to resolve after a single course of treatment, or if they recur after the end of treatment, then the course of treatment may be repeated.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Adverse reactions

Dogs:

Rare

(1 to 10 animals / 10,000 animals treated):

Drowsiness^a, Anorexia^a

Vomiting^a,b

Neurological symptom (e.g. somnolence, muscle tremor, ataxia, hyperactivity, convulsion)

Very Rare

(<1 animal / 10,000 treated, including isolated reports):

Hypotension^c

Allergic reaction (e.g. allergic oedema, urticaria, allergic dermatitis, pruritus)

^a usually moderate and transient

^b usually only occurs after the first administration. In this case treatment should not be discontinued, since the vomiting is unlikely to reoccur after the next administration.

^c transient

Cats:

Very Rare

(<1 animal / 10,000 treated, including isolated reports):

Drowsiness^a

Allergic reaction (e.g. allergic oedema, urticaria, allergic dermatitis, pruritus)

Neurological symptom (e.g. somnolence, muscle tremor, ataxia, hyperactivity, convulsion) Hypotension^b

Undetermined frequency (cannot be estimated from the available data)

Anorexia^a

Vomiting^a,c

^a usually moderate and transient

^b transient

^c usually only occurs after the first administration. In this case treatment should not be discontinued, since the vomiting is unlikely to reoccur after the next administration.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.